Akash Roy
@RoyAHep
Followers
2K
Following
5K
Media
109
Statuses
1K
Liver Specialist I Institute of Gastrosciences I Apollo Hospitals I Via PGIMER Chandigarh &SGPGIMS Lucknow I Executive Editor https://t.co/ryV6DeHeGJ
Kolkata, India
Joined April 2020
13
4
98
https://t.co/gD17oeOMXN ROTEM based transfusion strategy reduced prophylactic blood product transfusion for PLEX port insertion among ALF and ACLF patients @cmcvelloreoff @OffCMCVellore @joy_mammen
2
5
5
Advance Hepatology with JCEH 📊 Impact Factor: 3.2 📈 CiteScore: 5.1 ⏱️ Editorial decision: ~4.9 days ⚡ Online publication: ~4.9 days post-acceptance 📢 Now inviting high-impact liver research. 📝 Submit today 👇🏽 https://t.co/2E4qyL96mQ
@AnandVKulkarni2 @docMPK @ajay_duseja
1
2
4
🆕 @JCEH_Hepatology Sepsis remains a major threat in liver disease. This 📜 🔍 evolving pathophysiology, emerging biomarkers, AI-driven insights, and organ-specific strategies. A must-read from @MaiwallRakhi
jcehepatology.com
Sepsis is a leading cause of morbidity and mortality in critically ill patients, particularly those with underlying liver disease. The past decade has seen a paradigm shift in the understanding and...
1
1
3
Checkout @JCEH_Hepatology Pilot study of ascitic fluid proteomics in cirrhosis with spontaneous bacterial peritonitis. From the illustrious @drnipunverma
jcehepatology.com
Spontaneous bacterial peritonitis (SBP) is a life-threatening complication affecting 10–30% of patients with cirrhosis, with short-term mortality exceeding 30%(1). Presence of shock and each hour...
0
1
5
📜Just published in JCEH! Stool urease activity (SUA) better predicts OHE than NH3 📈 SUA linked to gut 🦠 activity & hyperammonemia. 🧫 ?novel biomarker for early OHE risk @ILBS_India
@drshivsarin @drnipunverma @AnandVKulkarni2 @drshalimar @kumarrahul0204
jcehepatology.com
Hyperammonemia is a key factor in genesis and outcome of overt hepatic encephalopathy (OHE). It is caused by both reduced hepatic ammonia clearance and increased production in gut by bacterial urease...
0
5
15
0
0
0
New @JCEH_Hepatology 🚨 🕐-restricted eating (TRE) supercharges insulin sensitivity in MASLD! 🥗⏰🔥 📊 TRE+Hypocaloric(HCD) vs HCD 🩺 HOMA-IR drop 2.6(TRE+HCD) vs 1.5(HCD) 🛠️ Steatosis 66.7% (TRE+HCD) vs 52.4%(HCD) @ajay_duseja @doc_arka @DrAshish_Kumar
jcehepatology.com
Insulin resistance is a key pathogenic mechanism in metabolic dysfunction-associated steatohepatitis (MASLD). Time-restricted eating (TRE) has the potential to restore insulin sensitivity in patients...
1
3
8
🚨 New 📜 @JCEH_Hepatology 270 LT patients ⏭️13 years 🫀 Coronary CTA identified CAD in 70% 💀 ⬆️ CAD-RADS - 📈 mortality ❌ CAC score did NOT ❤️ CAD-RADS 0–1 :0️⃣ MIs 👉 Coronary CTA 💪🏽 @LiverFellow
@_LTSI_ @INASL_Liver @_ILTS_
@RohitMehtaniDM @docMPK
jcehepatology.com
Cardiovascular risk stratification is crucial in patients with end-stage liver disease (ESLD) yet the optimal non-invasive strategy remains debated. Our study aimed to assess the prognostic value of...
0
2
5
📜 New @JCEH_Hepatology ACLF-Again after recovery 🔁 Median recurrence: 92 🗓️ ⚠️ Worse outcomes: higher AARC scores,OF 🚨 Key triggers: 🍺46% 🦠42% @ajay_duseja @AnandVKulkarni2 @drnipunverma @APASLnews @INASL_Liver @LiverFellow @DrAshish_Kumar
jcehepatology.com
Acute-on-Chronic Liver Failure-Again (ACLF-Again) is an entirely new and undiscovered entity in patients with chronic liver disease, can be defined as re-emergence of ACLF following reversal from an...
0
4
18
‘Point-of-Care Ultrasound (POCUS) guided volume management... : Hepatology https://t.co/c63bvQA9VZ Now online. #livertwitter @ajay_duseja @drnipunverma @AnandVKulkarni2 @hepocus @Florent_Artru @manhalizzy @ebtapper POCUS to classify volume status in Cirrhosis & AKI Trajectory
5
26
59
🚨 Just out in @HEP_Journal From 🌍 POCUS👸🏽 @docMPK POCUS 🎯volume management in AKI 💔 CCM 🔑determinant of outcomes 🔸3/4 with HRS have it 🧠 Dynamic, tailored 💦strategy improves AKI 📉 CCM = 8.9× ↑ ⚰️ @AnandVKulkarni2 @drnipunverma @ajay_duseja ⏬
journals.lww.com
and survival, in cirrhosis and AKI between January 2023 and November 2024. Exclusions were patients with structural cardiac disease, portopulmonary hypertension, acute variceal bleeding, and septic...
1
2
14
‘Point-of-Care Ultrasound (POCUS) guided volume management... : Hepatology https://t.co/c63bvQA9VZ. patients with AKI [84.7% men, aged 50.3±12 years, MELD-Na 23.9±5.1]; 296(79.6%), 42(11.3%), and 34(9.1%) were classified as hypovolemic, euvolemic, and hypervolemic at Timezero.
journals.lww.com
and survival, in cirrhosis and AKI between January 2023 and November 2024. Exclusions were patients with structural cardiac disease, portopulmonary hypertension, acute variceal bleeding, and septic...
1
13
29
Portal pressure tells part of the story, the patient tells the rest,” noted experts as they navigated ascites, encephalopathy, and recompensation strategies. Today’s session reminded clinicians to see beyond numbers and consider the patient’s overall condition in every management
0
1
10
The grand finale lecture Aptly delivered by @MajaThiele Fantastic deliberation #aigliverconclave @
0
3
16
Legends in Dialogue! Combining wisdom and inspiration, Dr. D. Nageshwar Reddy, Chairman, AIG Hospitals, engaged hepatology’s legends and pioneers from across the world in an informal, candid exchange, sharing career journeys, personal anecdotes, lessons learned, and thoughtful
1
2
19
Preventing 1st Decompensation From the master of Portal Hypertension Prof Garcia Tsao #aigliverconclave
0
7
38
Precision Medicine in Hepatology Futuristic visions from Prof Rajender Reddy #aigliverconclave
@AnandVKulkarni2
@manasa_alla
@miNitinjagtap
0
1
14